Are small clusters of cells that make up 5-day-old human embryos equivalent to children? Biologically and in terms of just common sense, the answer is “no.” These tiny spheres have around 100 cells and no organs. Actual people have many trillions of cells, brains, and other organs. Alabama law on embryos may block IVF About […]
What happens during brain aging and how can we tell if dementia is coming? Are there particular early hallmarks? There are an increasing number of medical tests for predicting or detecting dementia. Alzheimer’s disease can often be detected early. But what do patients or their doctors do with such information? Until recently there weren’t any
Weekly reads: brain aging, perinatal stem cell clinics, $1M lab meat fine bill Read More »
There’s a fascinating type of olfactory cell. These so-called tuft cells have unusual characteristics, especially for nose cells. I had never heard of them before until reading a new article. The inside of the nose may not seem like a very attractive place but there are cool “nose stem cells” in there. More broadly, there
Weekly reads: cool olfactory tuft cells, T-cell therapy, NK cells Read More »
Readers of The Niche have asked me many questions about stem cells for autoimmune disease but the puzzle of why women get these conditions more often than men hasn’t come up before here. For instance, why is MS so much more common in women than men? It’s remained somewhat of a mystery over the years.
Placental biologics firm MiMedx and exosome company Kimera Labs both recently received FDA warning letters. The letter to MiMedx was related to its placental biologics products and procedures. The new warning to Kimera Labs was about its exosome products and an amniotic product. Let’s compare these letters starting with the one to MiMedX. MiMedx warning letter
Weekly reads: MiMedX & Kimera Labs FDA warnings, NYT on Bryan Johnson, MUSE cell trial Read More »
The biotechs Vertex and CRISPR Therapeutics have an interesting relationship as biotechs. They are partners are multiple levels but also are very different as companies including in size. There’s been a key development in one of their partnerships. Before we jump into that, please check out the video version of my 20 stem cell and
Weekly reads: Vertex & CRISPR Therapeutics, Arnold Caplan death, MS genetics Read More »
I’m trying to remember the first time I ever heard about clones. It had to be as a kid. Maybe in a monster movie or TV show? Possibly a clone was referred to by the more general term “double”, which is not necessarily a clone. Whatever it was, I’m sure as a kid that I
Weekly reads: game of clones, super-SOX, Moonwalk Bio, Great Wall’s living skin Read More »
The FDA has a unique mechanism called RMAT or regenerative medicine advanced therapy designation. It’s intended to move investigational regenerative therapies forward more effectively. RMAT data I recently updated The Niche RMAT list and it has jumped to 85. The FDA has approved many new RMATs this year. The data on how many applications the FDA
The big news broke Friday that the FDA approved two new gene therapies for sickle cell disease. While the approvals were expected and the actual use of these treatments will be complex on several levels, this is a historic development. 2 FDA-approved gene therapies for sickle cell Friday’s news follows on recent UK approval for
For about as long as I’ve been writing The Niche, people have been asking about stem cells for MS. There’s a huge need for new therapies. While a chemo-based approach with autologous hematopoietic stem cell transplantation (HSCT) looks to work for certain cases of multiple sclerosis (although not yet approved in the US), other cell
Weekly reads: stem cells for MS, good news x2, extending dog years, Neuralink updates Read More »